Ionis Pharmaceuticals Completes Enrollment In Pivotal Cohort (Cohort 1) Of REVEAL Phase 3 Reveal Study Of Obudanersen (ION582) Angelman Synd

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS ) today announced that it has completed enrollment in the pivotal cohort (Cohort 1) of the global Phase 3 REVEAL study evaluating obudanersen (ION582), an investigational RNA-targeted medicine for people living with Angelman syndrome (AS), a serious and rare neurodevelopmental disorder associated with significant impairments in communication, physical function and cognition. The pivotal cohort enrolled 136 participants aged 2 to < 18 years old with a confirmed clinical diagnosis of AS with genetic confirmation of either a UBE3A deletion or UBE3A mutation. The adult cohort (Cohort 2) comprised of participants aged 18 to ≤ 50 years old living with AS is expected to complete enrollment in the third quarter of 2026. Topline data from the REVEAL study is expected in the second half of 2027. "Completion of enrollment in the pivotal cohort of REVEAL...